UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

MATINAS 1 BIOPHARMA Corporate Presentation April/May 2021 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact ar ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2020 Earnings Conference Call March 29, 2021 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer James Ferguson - Chief Medical Officer Raphael Mannino - Chief Scientific Officer Hui Liu - Chief Technology Officer Theresa Matkovits - Chief Development Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Gregory Fraser - Truist Securities Operator Hello ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1545 Route 206 Sout ...

| --- | --- | |------------------------|-------| | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | | | | | March 2021 | | | (NYSE AMER: MTNB) | 1 | Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that ...

| --- | --- | --- | |--------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation December 2020 | | | Forward-Looking Statement MTNB This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predi ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2020 Results Conference Call November 6, 2020 8:30 AM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Keith Kucinski - CFO Dr. James Ferguson - Chief Medical Officer Conference Call Participants Bert Hazlett - BTIG Yasmeen Rahimi - Piper Sandler Operator Greetings. Welcome to Matinas BioPharma Third Quarter 2020 Results Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal pre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) 908-443-1860 (Registrant's telephone num ...

| --- | --- | --- | |---------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation September 2020 | | | Forward-Looking Statement MTNB This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are pre ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Terri Matkovits - Chief Development Officer Conference Call Participants Michael Okunewitch - Maxim Group Gregg Gilbert - Truist Operator Welcome to the Matinas BioPharma Second Quarter 2020 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a rem ...